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ABSTRACT
Introduction: Metastases to the penis are rare, but can have severe consequences. 
The aim of this study was to systematically review the literature in order to gain more 
information on the presentation and prognosis of this metastatic disease.
We reviewed the literature relating to all case reports, series and reviews about 
penile metastasis, from 2003 to 2013, through a Medline search. We identified 63 
articles and 69 patients.
Metastases were located on the root (38.8%), the shaft (38.8%) or the glans 
(22.2%) of the penis. The diagnosis of penile metastasis was made after the primary 
cancer had been diagnosed. The most common presentation was a single small penile 
nodule. Ten patients reported priapism. The median survival time after diagnosis of 
penile metastasis was 10 months (range 6-18 months). A Kaplan-Meier analysis has 
shown that the patients presenting with priapism and those with metastases from 
non-urologic tumors have a significantly worse prognosis (age adjusted Log Rank: 
p=0.037 for priapism vs. no priapism and p=0.045 for urologic vs. non urologic).
There are prognostic differences based on the presentation of penile metastases. 
Survival is substantial and treatment should therefore take into account symptoms 
improvement and quality of life.
INTRODUCTION
Although penile metastasis is relatively rare, its 
management presents a challenging problem. The first 
description of a penile metastasis was published in 1870 
[1] and the first extensive review of the problem in 1961 
by Abeshouse et al. [2]. Since then, about 460 additional 
cases have been reported in literature.
The most common primary malignancies with 
penile metastases are urogenital cancers (69%) followed 
by cancers from gastrointestinal origin (19%) [1, 2, 3, 4, 
5, 6, 7, 8, 9, 10, 11, 12]. The clinical manifestations are 
heterogeneous, ranging from penile nodules to masses, 
with or without ulceration, obstructive or irritative urinary 
symptoms, hematuria or priapism. It has been suggested 
that the occurrence of priapism as a consequence of 
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malignancy may be a prognostic factor to take into 
account [2, 3, 5, 10, 12].
Priapism can be defined as a prolonged penile 
erection in absence of sexual stimulation, usually caused by 
hematological diseases such as sickle cell anemia, leukemia 
or polycythemia, pelvic thrombosis or thrombophlebitis, by 
neurological diseases or by extensive pelvic tumors with or 
without penile metastasis [2, 4, 5, 8]. Various mechanisms 
for priapism secondary to cancer have been suggested, 
including tumor infiltration of the corpora cavernosa or 
blockage of the cavernous venous drainage system [1]. 
Metastases to the penis mimicking priapism are extremely 
rare, especially in the absence of a disseminated disease.
Most cancers leading to penile metastasis are from 
pelvic organs: prostate and bladder followed by colon 
of the recto-sigmoid region. Priapism resulting from 
such metastases will often be clinically overlooked and 
therefore difficult to treat. Whether or not the occurrence 
of priapism secondary to penile metastases can be one of 
the major prognostic factors remains unknown and the aim 
of this systematic review is to clarify this question.
MATERIALS AND METHODS
Evidence acquisition
We conducted a search of the English language 
literature, ranging from 2003 to January 2013, using the 
Medline database of the US National Library of Medicine 
(http://www.ncbi.nlm.nih.gov/pubmed) and the Google 
Scholar database. The Medline search was carried out by 
using the following Medical Subject Headings (MESH) and 
free text terms: penile, and metastasis were combined with 
the terms ‘treatment, clinical manifestations, therapy’ and 
then limited to ‘humans, male and young adult, 19-24 years’.
Abstracts were excluded if subsequently followed 
by extended articles. Overlapping reports were not 
considered because of redundant information. From the 
initial literature search yielding 843 unique citations, a 
total of 63 papers were selected to review. Out of these 
63 papers, 69 patients and their data were used for the 
analysis [1-51]. The Prisma Statement was used to perform 
an accurate research check-list and report (Figure 1).
Figure 1: Articles’ selection process.
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Statistical analysis
For the null hypothesis, we assumed that there was 
no difference in terms of outcome between all clinical, 
pathological and instrumental parameters in patients 
affected by secondary penile malignancy. Fisher’s exact 
test and chi-square test were used to assess the significance 
of differences between parameters, with p<0.05 considered 
the cut-off for significance. Categorical variables were 
presented as percentages and were compared using χ2 
analysis. Continuous variables were presented as the mean 
± standard deviation and were compared using Student’s 
t-test or the Mann–Whitney U-test.
Relative Risks and 95% confidence intervals were 
estimated by applying log-binomial regression and Cox 
regression analysis with a constant in the time variable. 
Moreover, difference in survival were assessed by Kaplan 
Meyer survival curves (and age adjusted log rank). All 
reported p values are 2-sided. Statistical analyses were 
performed using SPSS 11.0 for Apple-Macintosh (SPSS, 
Chicago, Illinois).
RESULTS
The population for analysis consisted of patients 
with an age range of 57 to 92 years and a mean follow-up 
of 15.6 months (range 5-30). The clinical characteristics of 
the patients are given in Table 1.
Clinical presentation and treatment
Penile metastases were located at the root (38.8%), 
the shaft (38.8%) or the glans (22.2%) of the penis. 
Five patients had multiple penile metastatic lesions. 
In four patients the diagnosis of penile metastasis was 
Table 1: Clinical characteristics of the patients
Primary tumour Prostate TCC Other
No. of cases 17 13 39






Localization root (n.) 3 3 2
Shaft 2 3 3
Glans 3 0 1
unknown 9 7 33






Presentation painless nodule 10 5 21
Priapism 2 3 5
other symptoms 2 3 5
Unknown 3 2 7
Timing of diagnosis vs. diagnosis of 
primary tumor
Synchronous 1 1 2
Metachronous 8 1 4
Unknown 8 11 33
Treatment LHRH analogue 4
total penectomy 1 1
radical cystoprostatectomy 1
conservative penile sparing therapy 1
intravenous temsirolimus 1
None 1
Unknown treatment 11 10 38
Cancer specific survival mean % died 66.7 83.3 80
mean follow-up time (months) 16.4 19.2 11.2
Oncotarget2926www.impactjournals.com/oncotarget
synchronous with the diagnosis of the primary tumor, but 
metachronous in the majority. The most common form 
of presentation was a single small painless nodule of 1-2 
cm in diameter. Ten patients presented with priapism 
secondary to penile metastasis.
Pathological considerations
In 33 cases (47.8%), the primary cancer originated 
from the urogenital tract, prostate cancer in 17 cases 
(24,6%), bladder cancer in 13 (18,8%), renal cancer in 2 
(2,9%) and seminal vesicle cancer in one patient (1,5%). 
36 cases (52,2%) originated from other cancers such as 
skin, lung, colorectal, esophagus, tongue, jaw, thyroid, 
testis, lymphoma and glomangiosarcoma.
Survival analysis
The median cancer-specific survival time for men 
with penile metastasis was 14.5 months (range 5-30). The 
Kaplan-Meier curve analysis showed that patients with 
metastases from non-urological tumors generally seemed 
to have a poorer prognosis than those with tumours of 
urological origin (Figure 2) and that patients presenting 
with malignant priapism had a worse prognosis than those 
without priapism (Figure 2). Thus, patients with priapism 
as the presenting symptom from a metastasis originating 
from a non-urological malignancy had a worse prognosis 
compared to those with metastases from urological 
malignancies and without priapism (age adjusted log rank 
p=0.045 for urological vs. non-urological and p=0.037 for 
priapism vs. no priapism) (Figure 3).
30 patients with urological metastases (43%) had 
a median cancer specific survival time of 18 months 
compared to 30 patients with non urological metastases 
(57%) who had a median cancer specific survival time of 
11 months.
10 patients presented with priapism as the first 
symptom (5 from urological and 5 from non-urological 
cancers). Patients with priapism from urological cancer 
had a median cancer specific survival time of 30 months, 
patients with priapism from non-urological cancer had 
a median cancer specific survival time of 15 months 
(Figure 4).
DISCUSSION
Penile metastases are relatively rare and usually 
occur in the context of more widespread disseminated 
Figure 2: Kaplan-Meier curve, patients with metastases from urological and non-urological tumors.
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disease. Therefore, the prognosis is significantly poor. 
However, little more than this is known about the 
problem.
As penile metastases are only reported in case 
reports or small case series there will never be reliable 
evidence from larger trials from prospective series. Thus, 
Figure 3: Kaplan-Meier curve, details of patients with metastases from urological and non-urological tumors and 
presence of malignant priapism.
Figure 4: CT-scan of metastasis plus histological section.
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the only evidence that can be used to gather information 
about penile metastases is from case reports. Therefore, 
we analysed the available literature on case reports of 
penile metastases in order to gain more information.
Our analysis is the most comprehensive systematic 
review of the topic with a clinically relevant number of 
cases. Moreover, we performed our analysis on all cases of 
penile metastasis without excluding patients based on the 
site of the primary malignancy or the presentation. This 
approach has, of course, several limitations as its nature 
is retrospective, making it therefore impossible to assess 
data other than those reported by the primary authors. 
However, we excluded patients with incomplete clinical 
or pathological data, i.e. when survival time or pathology 
of the primary tumor were not given. Another limitation 
is that it was impossible to draw any conclusion on the 
impact of the treatment from the case reports we analysed.
Thus, our limited analysis shows that penile 
metastases presenting with priapism have a very poor 
prognosis, especially if the primary tumor is not of 
prostatic or bladder origin. However, based on the 
published cases, the mean survival time is 14 months 
and this data has to be considered in view of a possible 
disseminated disease, which could in turn cause other 
symptoms.
Our finding that malignant priapism is associated 
with a poorer prognosis in patients with penile metastases 
is consistent with other previous reports. Whilst penile 
metastases most commonly appear as an infiltrative lesion 
or nodule, up to 40% of cases reported intermittent or 
continuous malignant priapism. This was first described 
in 1938 by Peacock.
A literature review by Lin YH et al based on reports 
from 2006 to 2011 suggested that the true incidence of 
penile metastasis may be higher given that 12% of penile 
metastasis may be asymptomatic and discovered only at 
autopsy. They also suggested that most cases of malignant 
priapism would be low-flow priapism due to neoplastic 
invasion of cavernous sinuses and venous system [2]. 
While this theory seems to be highly plausible, some 
authors have suggested that malignant priapism may also 
be due to high flow in some cases. Dubocq et al used 
doppler ultrasound and have found evidence for this 
theory in their cases. Differences in the pathophysiology 
of malignant priapism may also be related to the mode of 
the metastatic spread. Whilst urological cancers may also 
invade the penile cavernous bodies directly, non-urological 
metastases will occur from lymphatic or hematogenous 
spread.
We calculated a mean survival time of the reported 
cases of 14 months. Lin YH et al. reported an average 
cancer-specific survival time of 9 months with an overall 
survival time of under 18 months. According to our analysis, 
survival time is over one year and therefore is a substantial 
data for planning a treatment. Whilst the treatment approach 
is commonly palliative, this may be questioned in view of 
the survival time. According to our review, in patients with 
better prognostic indicators (urological cancer, no priapism), 
the efforts of the treatment should be on prolonging the 
survival time and enhancing the quality of life.
CONCLUSIONS
Whilst penile metastasis is rare and is only one of 
the manifestations of a disseminating cancer, there are 
differences in prognosis between patients presenting with 
or without priapism and those with urological or non-
urological primary cancers. Cancer-specific survival time 
is on average substantial with over one year and treatment 
should take this data into consideration.
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